Pancreatic cancer is among the leading causes of cancer-related deaths with extremely poor prognosis. Thus, novel and effective therapies need to be developed to improve the poor survival rates of patients with advanced pancreatic cancer. Pectolinarigenin, a flavonoids compound, has been shown to possess numerous biologic activities such as anti-inflammation and anti-cancer. However, the function and mechanism of pectolinarigenin in pancreatic cancer are still not well understood. We evaluated the antitumor effects of pectolinarigenin, an active component of a medicinal plant. Pectolinarigenin exerted a strong antitumor effect in pancreatic cancer cell lines. Colony formation assay and wound healing assay indicated that pectolinarigenin inhibited cell viability and cell migration. Treatment with pectolinarigenin induced apoptosis and decreased phosphorylation of STAT3. Pectolinarigenin modulates the STAT3 signaling module, thereby inducing cytotoxicity in pancreatic cancer cells. This result verifies the potential use of pectolinarigenin as a new therapeutic agent for the treatment pancreatic cancer.
ChenW, ZhengR, BaadePD, ZhangS, ZengH, BrayF, JemalA, YuXQ, HeJ. (2016) Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115–132.
2.
SiegelRL, MillerKD, JemalA. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7–30.
3.
GuptaR, AmanamI, ChungV. (2017) Current and future therapies for advanced pancreatic cancer. Journal of Surgical Oncology, 116, 25–34.
4.
GongJ, MunozAR, PingaliS, Payton-StewartF, ChanDE, FreemanJW, GhoshR, KumarAP. (2017) Downregulation of STAT3/NF-kappaB potentiates gemcitabine activity in pancreatic cancer cells. Molecular Carcinogenesis, 56, 402–411.
5.
AvalleL, CamporealeA, CamperiA, PoliV. (2017) STAT3 in cancer: A double edged sword. Cytokine, 98, 42–50.
6.
YuH, LeeH, HerrmannA, BuettnerR, JoveR. (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nature Reviews Cancer, 14, 736–746.
7.
YuanJ, YangY, GaoZ, WangZ, JiW, SongW, ZhangF, NiuR. (2017) Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer Research and Treatment, 164, 327–340.
8.
ZhaoC, LiH, LinHJ, YangS, LinJ, LiangG. (2016) Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends in Pharmacological Sciences, 37, 47–61.
9.
SawickiM, SzudyA, SzczyrekM, KrawczykP, KlatkaJ. (2012) Molecularly targeted therapies in head and neck cancers. Polish Otolaryngology, 66, 307–312.
10.
KoAH, TemperoMA. (2002) Current and future strategies for combined-modality therapy in pancreatic cancer. Current Oncology Reports, 4, 202–212.
11.
YuH, PardollD, JoveR. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer, 9, 798–809.
LimH, SonKH, ChangHW, BaeK, KangSS, KimHP. (2008) Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum. Biological & Pharmaceutical Bulletin, 31, 2063–2067.
14.
WangC, ChengY, LiuH, XuY, PengH, LangJ, LiaoJ, LiuH, LiuH, FanJ. (2016) Pectolinarigenin suppresses the tumor growth in nasopharyngeal carcinoma. Cellular Physiology and Biochemistry, 39, 1795–1803.
15.
BonesiM, TundisR, DeguinB, LoizzoMR, MenichiniF, TillequinF, MenichiniF. (2008) In vitro biological evaluation of novel 7-O-dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell lines. Bioorganic & Medicinal Chemistry Letters, 18, 5431–5434.
16.
ShiL, ZhengH, HuW, ZhouB, DaiX, ZhangY, LiuZ, WuX, ZhaoC, LiangG. (2017) Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer. Onco Targets & Therapy, 10, 1767–1776.
17.
MaceTA, AmeenZ, CollinsA, WojcikS, MairM, YoungGS, FuchsJR, EubankTD, FrankelWL, Bekaii-SaabT, BloomstonM, LesinskiGB. (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Research, 73, 3007–3018.
18.
HuY, ZhaoC, ZhengH, LuK, ShiD, LiuZ, DaiX, ZhangY, ZhangX, HuW, LiangG. (2017) A novel STAT3 inhibitor HO-3867 induces cell apoptosis by reactive oxygen species-dependent endoplasmic reticulum stress in human pancreatic cancer cells. Anti-cancer Drugs, 28, 392–400.
19.
HosseiniM, HassanianSM, MohammadzadehE, ShahidSalesS, MaftouhM, FayazbakhshH, KhazaeiM, AvanA. (2017) Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Journal of Cellular Biochemistry, 118, 1634–1638.
20.
OzawaF, FriessH, KunzliB, ShrikhandeSV, OtaniT, MakuuchiM, BuchlerMW. (2001) Treatment of pancreatic cancer: the role of surgery. Digestive Diseases, 19, 47–56.
21.
ZhangXW, MaYX, SunY, CaoYB, LiQ, XuCA. (2017) Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Targeted Oncology, 12, 309–321.
22.
BartonLA, RenJ. (2016) Pancreatic Neoplasms and Autophagy. Current drug Targets, 17, 1–6.
